Metabolic Impact of Diabetes Mellitus Type 2 in Hepatitis C Virus Infected Patients.

Autor: Popescu MS; Internal Medicine Department, University of Medicine and Pharmacy of Craiova, Romania., Firu DM; Internal Medicine Department, University of Medicine and Pharmacy of Craiova, Romania., Mitruţ R; Cardiology Department, University of Medicine and Pharmacy of Craiova, Emergency University Hospital of Bucharest, Romania., Mărgăritescu DN; Surgery Department, University of Medicine and Pharmacy of Craiova, Romania., Kamal AM; Internal Medicine Department, University of Medicine and Pharmacy of Craiova, Romania., Pădureanu V; Internal Medicine Department, University of Medicine and Pharmacy of Craiova, Romania., Mitruţ P; Internal Medicine Department, University of Medicine and Pharmacy of Craiova, Romania.
Jazyk: angličtina
Zdroj: Current health sciences journal [Curr Health Sci J] 2021 Jul-Sep; Vol. 47 (3), pp. 405-411. Date of Electronic Publication: 2021 Sep 30.
DOI: 10.12865/CHSJ.47.03.11
Abstrakt: Objective: Patients with chronic hepatitis C are subjected to a greater risk of cardiovascular disease and difficult to control diabetes mellitus type 2 (T2DM) comparatively to people that have never contracted Hepatitis C Virus (HCV). We aimed to investigate the impact of T2DM on HCV patients with the help of Fibromax test results compared to nonT2DM patients, and the metabolic differences between the 2 study groups. Our long term goals are to observe the long term impact of achieving systemic virusologic response (SVR) by means of Direct-Acting antivirals (DAA) between the 2 cohorts.
Research Design and Methods: We selected a lot of 200 patients with HCV that will undergo interferon-free DAA-based antiviral treatment for HCV and we used the results of the Fibromax Test to compare the biological parameters of T2DM and nonT2DM patients. RESULTS Among patients with T2DM compared to NonT2DM there is a significant correlation on Steatotest, NashTest, GGT, Glycemia, body weight, height and BMI. Test also showed that 15,5% of the test group had elevated glycemia, indicating the probability of developing diabetes in the future.
Conclusions: Our results suggest that HCV patients that also have T2DM are subjected to a combined higher risk of accelerated steatosis development, steatohepatitis, added difficulty in controlling glycemic levels. All these previous elements combined with a prevalence for patients to be overweight have a negative metabolic impact. Eradication of HCV with the help of DAA is important in order to help improving the metabolic impact of diabetes on steatosis, steatohepatitis. An added benefit is better management of glycemic control by decreasing insulin use and eliminating one risk factor of T2DM.
Competing Interests: The authors declare that there is no conflict of interest.
(Copyright © 2014, Medical University Publishing House Craiova.)
Databáze: MEDLINE
Externí odkaz: